NO20042990L - Pyrrolidin-2-oner som faktor XA inhibitorer - Google Patents
Pyrrolidin-2-oner som faktor XA inhibitorerInfo
- Publication number
- NO20042990L NO20042990L NO20042990A NO20042990A NO20042990L NO 20042990 L NO20042990 L NO 20042990L NO 20042990 A NO20042990 A NO 20042990A NO 20042990 A NO20042990 A NO 20042990A NO 20042990 L NO20042990 L NO 20042990L
- Authority
- NO
- Norway
- Prior art keywords
- pyrrolidin
- inhibitors
- ones
- factor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Surgery (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pyrrole Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0130705.7A GB0130705D0 (en) | 2001-12-21 | 2001-12-21 | Chemical compounds |
| PCT/EP2002/014826 WO2003053925A1 (en) | 2001-12-21 | 2002-12-20 | Pyrrolidine-2-ones as factor xa inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20042990L true NO20042990L (no) | 2004-09-20 |
Family
ID=9928210
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20042990A NO20042990L (no) | 2001-12-21 | 2004-07-13 | Pyrrolidin-2-oner som faktor XA inhibitorer |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20050059726A1 (ko) |
| EP (1) | EP1456172A1 (ko) |
| JP (1) | JP2005519885A (ko) |
| KR (1) | KR20040072666A (ko) |
| CN (1) | CN100364971C (ko) |
| AR (1) | AR037928A1 (ko) |
| AU (1) | AU2002366747A1 (ko) |
| BR (1) | BR0215200A (ko) |
| CA (1) | CA2471461A1 (ko) |
| CO (1) | CO5590896A2 (ko) |
| GB (1) | GB0130705D0 (ko) |
| HU (1) | HUP0500137A2 (ko) |
| IL (1) | IL162454A0 (ko) |
| IS (1) | IS7316A (ko) |
| MX (1) | MXPA04006139A (ko) |
| MY (1) | MY141579A (ko) |
| NO (1) | NO20042990L (ko) |
| NZ (1) | NZ533129A (ko) |
| PL (1) | PL371008A1 (ko) |
| RU (1) | RU2318807C2 (ko) |
| TW (1) | TWI262075B (ko) |
| WO (1) | WO2003053925A1 (ko) |
| ZA (1) | ZA200404147B (ko) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200307667A (en) | 2002-05-06 | 2003-12-16 | Bristol Myers Squibb Co | Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors |
| JP2006527732A (ja) | 2003-06-19 | 2006-12-07 | グラクソ グループ リミテッド | Ｘａ因子の阻害剤としての３−スルホニルアミノ−ピロリジン−２−オン誘導体 |
| GB0314299D0 (en) | 2003-06-19 | 2003-07-23 | Glaxo Group Ltd | Chemical compounds |
| GB0314373D0 (en) | 2003-06-19 | 2003-07-23 | Glaxo Group Ltd | Chemical compounds |
| GB0314370D0 (en) * | 2003-06-19 | 2003-07-23 | Glaxo Group Ltd | Chemical compounds |
| US7169795B2 (en) | 2003-09-30 | 2007-01-30 | Bristol Myers Squibb Company | Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors |
| BRPI0513713A (pt) * | 2004-07-28 | 2008-05-13 | Glaxo Group Ltd | derivados de piperazina úteis para o tratamento de distúrbios gastrointestinais |
| DE102004062544A1 (de) * | 2004-12-24 | 2006-07-06 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue substituierte Pyrrolidinone, deren Herstellung und deren Verewendung als Arzneimittel |
| DE102005008649A1 (de) * | 2005-02-25 | 2006-09-07 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue substituierte Pyrrolidinone, deren Herstellung und deren Verwendung als Arzneimittel |
| WO2006108709A1 (en) * | 2005-04-11 | 2006-10-19 | Glaxo Group Limited | 3-sulfonylamino-pyrrolidine-2-one derivatives as factor xa inhibitors |
| JPWO2006137527A1 (ja) | 2005-06-23 | 2009-01-22 | 協和発酵キリン株式会社 | チアゾール誘導体 |
| LT1921077T (lt) | 2005-08-02 | 2017-09-25 | Kyowa Hakko Kirin Co., Ltd. | Agentas, skirtas miego sutrikimo gydymui ir (arba) prevencijai |
| US7622492B2 (en) | 2005-08-31 | 2009-11-24 | Hoffmann-La Roche Inc. | Pyrazolones as inhibitors of 11β-hydroxysteroid dehydrogenase |
| EP1951712A2 (en) * | 2005-11-24 | 2008-08-06 | Glaxo Group Limited | Chemical compounds |
| WO2007117191A1 (en) | 2006-04-07 | 2007-10-18 | Bactiguard Ab | Novel antimicrobial substrates and uses thereof |
| CA2662574A1 (en) * | 2006-09-22 | 2008-03-27 | Novartis Ag | Heterocyclic organic compounds |
| CN116003280A (zh) * | 2022-12-30 | 2023-04-25 | 合肥工业大学 | 一种芳基甲酰胺类化合物的光化学合成方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5202344A (en) * | 1990-12-11 | 1993-04-13 | G. D. Searle & Co. | N-substituted lactams useful as cholecystokinin antagonists |
| US6034093A (en) * | 1995-06-07 | 2000-03-07 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Substituted sulfonic acid N-[(aminoiminomethyl)phenylalkyl]-azaheterocyclylamide compounds |
| US5731315A (en) * | 1995-06-07 | 1998-03-24 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Substituted sulfonic acid n- (aminoiminomethyl)phenylalkyl!-azaheterocyclamide compounds |
| US6403632B1 (en) * | 2000-03-01 | 2002-06-11 | Bristol Myers Squibb Pharma Co | Lactam metalloprotease inhibitors |
| US6025358A (en) * | 1998-06-11 | 2000-02-15 | G. D. Searle & Co. | Double prodrugs of potent GP IIb/IIIa antagonists |
| GB0114005D0 (en) * | 2001-06-08 | 2001-08-01 | Glaxo Group Ltd | Chemical compounds |
| TW200307667A (en) * | 2002-05-06 | 2003-12-16 | Bristol Myers Squibb Co | Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors |
| US7169795B2 (en) * | 2003-09-30 | 2007-01-30 | Bristol Myers Squibb Company | Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors |
-
2001
- 2001-12-21 GB GBGB0130705.7A patent/GB0130705D0/en not_active Ceased
-
2002
- 2002-12-19 AR ARP020105014A patent/AR037928A1/es not_active Application Discontinuation
- 2002-12-19 MY MYPI20024789A patent/MY141579A/en unknown
- 2002-12-19 TW TW091136597A patent/TWI262075B/zh not_active IP Right Cessation
- 2002-12-20 RU RU2004122427/04A patent/RU2318807C2/ru not_active IP Right Cessation
- 2002-12-20 BR BR0215200-2A patent/BR0215200A/pt not_active IP Right Cessation
- 2002-12-20 CN CNB028282248A patent/CN100364971C/zh not_active Expired - Fee Related
- 2002-12-20 AU AU2002366747A patent/AU2002366747A1/en not_active Abandoned
- 2002-12-20 IL IL16245402A patent/IL162454A0/xx unknown
- 2002-12-20 NZ NZ533129A patent/NZ533129A/en unknown
- 2002-12-20 CA CA002471461A patent/CA2471461A1/en not_active Abandoned
- 2002-12-20 WO PCT/EP2002/014826 patent/WO2003053925A1/en active Application Filing
- 2002-12-20 KR KR10-2004-7009675A patent/KR20040072666A/ko not_active Application Discontinuation
- 2002-12-20 HU HU0500137A patent/HUP0500137A2/hu unknown
- 2002-12-20 JP JP2003554642A patent/JP2005519885A/ja active Pending
- 2002-12-20 EP EP02805350A patent/EP1456172A1/en not_active Withdrawn
- 2002-12-20 US US10/499,529 patent/US20050059726A1/en not_active Abandoned
- 2002-12-20 MX MXPA04006139A patent/MXPA04006139A/es active IP Right Grant
- 2002-12-20 PL PL02371008A patent/PL371008A1/xx not_active Application Discontinuation
-
2004
- 2004-05-27 ZA ZA200404147A patent/ZA200404147B/en unknown
- 2004-06-16 IS IS7316A patent/IS7316A/is unknown
- 2004-06-18 CO CO04057414A patent/CO5590896A2/es not_active Application Discontinuation
- 2004-07-13 NO NO20042990A patent/NO20042990L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| MY141579A (en) | 2010-05-14 |
| NZ533129A (en) | 2006-12-22 |
| CN1620434A (zh) | 2005-05-25 |
| CO5590896A2 (es) | 2005-12-30 |
| WO2003053925A1 (en) | 2003-07-03 |
| JP2005519885A (ja) | 2005-07-07 |
| US20050059726A1 (en) | 2005-03-17 |
| MXPA04006139A (es) | 2004-11-01 |
| PL371008A1 (en) | 2005-06-13 |
| TW200306178A (en) | 2003-11-16 |
| RU2318807C2 (ru) | 2008-03-10 |
| CA2471461A1 (en) | 2003-07-03 |
| ZA200404147B (en) | 2005-06-21 |
| GB0130705D0 (en) | 2002-02-06 |
| RU2004122427A (ru) | 2006-01-20 |
| TWI262075B (en) | 2006-09-21 |
| IS7316A (is) | 2004-06-16 |
| CN100364971C (zh) | 2008-01-30 |
| AU2002366747A1 (en) | 2003-07-09 |
| AR037928A1 (es) | 2004-12-22 |
| EP1456172A1 (en) | 2004-09-15 |
| HUP0500137A2 (en) | 2006-02-28 |
| KR20040072666A (ko) | 2004-08-18 |
| BR0215200A (pt) | 2004-10-13 |
| IL162454A0 (en) | 2005-11-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20042592L (no) | Indol-2-karboksamider som faktor XA inhibitorer | |
| NO20041163L (no) | Laktam-inneholdende forbindelser og derivater derav som faktor XA-inhibitorer | |
| AU2002350217A8 (en) | Glycinamides as factor xa inhibitors | |
| NO20021230L (no) | Faktor Xa inhibitorer | |
| IL169323A0 (en) | Pyrazole-derivatives as factor xa inhibitors | |
| DK1140941T3 (da) | Nitrogenholdige heterobicykliske forbindelser som faktor Xa-inhibitorer | |
| NO20033593D0 (no) | Kinazoliner som MMP-13 inhibitorer | |
| DE60234125D1 (de) | E inhibitoren | |
| NO20035775L (no) | 3-fluor-pyrrolidiner som anti-diabetesmidler | |
| IS7793A (is) | Nýtt efnasamband | |
| IS7794A (is) | Nýtt efnasamband | |
| AU2002365896A8 (en) | Substituted amino methyl factor xa inhibitors | |
| NO20042990L (no) | Pyrrolidin-2-oner som faktor XA inhibitorer | |
| NO20033350L (no) | Imidazolyl-derivater som kortikotropin-frigjörende faktor inhibitorer | |
| DK1395553T3 (da) | Pyrrolidinderivater som faktor Xa-inhibitorer | |
| DE60216067D1 (de) | Flammhemmende intumeszenzbeschichtung | |
| HK1089174A1 (en) | Benzimidazole-derivatives as factor xa inhibitors | |
| NO20041819L (no) | Diazacykloalakaner som oksytocinagonister | |
| DE60325848D1 (de) | Flammwidrige zusammensetzungen | |
| NO20014234D0 (no) | Pyrazol-3-on-derivater som faktor-Xa-inhibitorer | |
| HK1089175A1 (en) | Azaindole-derivatives as factor xa inhibitors | |
| DE60206376D1 (de) | Faktor xa inhibitor | |
| BRPI0311588A2 (pt) | revestimento | |
| DE60319277D1 (de) | Beschichtungszusammensetzung | |
| AU2002325882A1 (en) | Phenyl derivatives as factor Xa inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |